A recent study, published in Nature Communications, focuses on the interaction between free fatty acids (FFAs) and GPR84, a G protein-coupled receptor (GPCR).
Nov 22, 2023
0
0
After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the ...
Nov 16, 2023
0
1
For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study ...
Nov 16, 2023
0
1
The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural mesothelioma, according to a study published online Nov. ...
Nov 15, 2023
0
0
Considering the molecular subtype of muscle-invasive bladder cancer (MIBC) based on differences in tumor RNA expression can improve the ability of an existing tumor biomarker, such as the COXEN score, to predict which patients' ...
Nov 15, 2023
0
0
A proposed federal policy aims to protect older Americans from contracting HIV by offering free preventive medication, the latest effort to catch up to much of Europe and Africa in stemming the spread of the virus.
Nov 14, 2023
0
0
Spend some time scrolling social media and you're all-but-guaranteed to see an ad promising to help you with targeted fat loss. These ads promote a concept known as "spot reduction," claiming you can burn fat in a specific ...
Nov 1, 2023
0
11
Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement ...
Oct 26, 2023
0
1
For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct. ...
Oct 25, 2023
0
1
For patients with chemorefractory metastatic colorectal cancer, the KRAS G12C inhibitor sotorasib in combination with the epidermal growth factor receptor inhibitor panitumumab results in longer progression-free survival ...
Oct 24, 2023
0
0
